EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Protocol for the Development of a Core Outcome Set for Inherited Ichthyosis

Vanya Rossel, S Vanya J Rossel, Jason Shourick, Maria C Bolling, Anna M G Pasmooij, Karin Veldman, Jamie J Kirkham, Juliette Mazereeuw-Hautier, Antoni H Gostyński

Dermatology · 29.04.2025 · 241 (4) · 348-355

DOI: 10.1159/000546035 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Dermatology, online erschienen am 29.04.2025. Verfasst von Vanya Rossel und 8 weiteren Autor:innen. Beteiligte Einrichtung: GROW School for Oncology Reproduction, Maastricht University, Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Ichthyosis, Outcome Assessment, Health Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Inherited ichthyosis comprises a group of rare keratinization disorders caused by abnormal epidermal barrier function. Ichthyosis is yet incurable and current treatments mainly focus on alleviating symptoms such as scaling, erythema and pruritus. Recent developments show promising results for interventions based on the immune-phenotype like biologicals or pathogenesis-based therapies such as gene therapy. However, the lack of uniform reporting and variety of treatment outcomes may complicate performing and comparing efficacy studies. The core outcome set for inherited ichthyosis (COSII) aims to develop a core outcome set (COS), i.e., the minimum of outcomes that should be measured and reported in observational and interventional studies, including a minimum set of baseline characteristics.

Methods

The COSII project will follow the guidelines from the Core Outcome Measures in Effectiveness Trials (COMET) initiative, including the Core Outcome Set-Standards for Development (COS-STAD) recommendations and the Core Outcome Set Standardised Protocol (COS-STAP) checklist. The COS development methodology, including this protocol, follows the guidance of the CHORD COUSIN Collaboration ‘C3’. The first stage of this project involves identifying a possible list of outcomes through performing a scoping literature review and conducting interviews with patient(s) (representatives). This list will be presented to five different stakeholder groups: healthcare professionals, researchers, patient(s) (representatives), industry representatives, and regulators. All stakeholders will rate the importance of each outcome in a three-round eDelphi survey. Ultimately, a virtual consensus meeting will be convened to finalize the COS. Ethical approval was obtained prior to the start of this project from the Medical Ethics Committee Board at Maastricht University Medical Centre (METC 2022-3192). Informed consent will be asked prior to enrolment in the eDelphi. This study is registered with the COMET. The results will be distributed via a peer-reviewed journal, communicated to all relevant parties and showcased at national and international conferences.

Conclusion

This will be the first COS for inherited ichthyosis research in accordance with the Core Outcome Measures in Effectiveness Trials initiative. The development of a COS aims to improve the consistency of reporting and the heterogeneity of outcomes in ichthyosis research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IchthyosisOutcome Assessment, Health CareHumansResearch Design

Stichwörter der Autor:innen

Core outcome setDelphi studyIchthyosisStudy protocolTreatment outcome

Autor:innen und Institutionen

  • GROW School for Oncology Reproduction, Maastricht University, Maastricht, The Netherlands.
  • Department of Dermatology, Centre of Expertise for Genodermatoses, Maastricht University Medical Centre+, Maastricht, The Netherlands.
  • Department of Clinical Epidemiology and Public Health, CHU Toulouse, Toulouse, France.
  • Department of Dermatology, Centre of Expertise for Genodermatoses, Groningen University Medical Centre, Groningen, The Netherlands.
  • Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
  • Dutch Patient Association for Ichthyosis Networks, The Netherlands and Member of European Patient Advocacy Group, European Network Ichthyosis, Groningen, The Netherlands.

Zitieren

APA

Rossel, V., Rossel, S. V. J., Shourick, J., Bolling, M. C., Pasmooij, A. M. G., Veldman, K., Kirkham, J. J., Mazereeuw-Hautier, J., & Gostyński, A. H. (2025). Protocol for the Development of a Core Outcome Set for Inherited Ichthyosis. Dermatology, 241(4), 348-355. https://doi.org/10.1159/000546035

Vancouver

Rossel V, Rossel SVJ, Shourick J, Bolling MC, Pasmooij AMG, Veldman K, et al. Protocol for the Development of a Core Outcome Set for Inherited Ichthyosis. Dermatology. 2025;241(4):348-355. doi:10.1159/000546035

BibTeX
@article{Rossel2025,
  author = {Rossel, Vanya and Rossel, S Vanya J and Shourick, Jason and Bolling, Maria C and Pasmooij, Anna M G and Veldman, Karin and Kirkham, Jamie J and Mazereeuw-Hautier, Juliette and Gostyński, Antoni H},
  title = {Protocol for the Development of a Core Outcome Set for Inherited Ichthyosis},
  journal = {Dermatology},
  year = {2025},
  volume = {241},
  number = {4},
  pages = {348--355},
  doi = {10.1159/000546035}
}
Kostenlos starten →